Taysha Gene Therapies, Inc. TSHA Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $319.77M+130% | $139.04M-3.4% | $143.94M+63.8% | $87.88M-41.1% | ||
| $449K0.0% | $449K0.0% | $449K-83.0% | $2.64M0.0% | ||
| $13.31M-1.5% | $13.51M-49.9% | $26.97M-29.2% | $38.09M-3.9% | ||
| —— | —— | $2M— | —— | ||
| $324.65M+128% | $142.13M-5.2% | $149.87M+55.4% | $96.42M-39.6% | ||
| $6.74M-10.0% | $7.49M-30.9% | $10.83M-27.6% | $14.96M-70.4% | ||
| $9.44M+12.6% | $8.38M-12.5% | $9.58M-12.4% | $10.94M— | ||
| $183K-15.7% | $217K-28.6% | $304K-76.9% | $1.32M+18.9% | ||
| $343.32M+114% | $160.36M-7.2% | $172.73M+36.8% | $126.28M-41.0% | ||
| $23.75M-14.0% | $27.62M-17.9% | $33.65M-53.4% | $72.16M+33.0% | ||
| $20.28M+57.7% | $12.86M+4.7% | $12.28M-32.8% | $18.29M-39.0% | ||
| —— | $9.77M-46.0% | $18.11M-46.0% | $33.56M— | ||
| $1.49M0.0% | $1.49M+15.0% | $1.29M+7.6% | $1.2M— | ||
| $379K-3.1% | $391K+10.5% | $354K+10.6% | $320K— | ||
| $26.55M+1.2% | $26.23M-28.6% | $36.76M-41.5% | $62.79M+21.3% | ||
| $50.11M+14.0% | $43.94M+8.5% | $40.51M+6.7% | $37.97M+2.1% | ||
| $18.17M+4.7% | $17.36M-8.4% | $18.95M-7.3% | $20.44M— | ||
| $379K-50.8% | $770K-32.0% | $1.13M-22.0% | $1.45M— | ||
| $19.66M+4.3% | $18.85M-6.9% | $20.25M-6.5% | $21.64M— | ||
| $1.55M+18.6% | $1.31M-17.0% | $1.58M-61.8% | $4.13M+10.6% | ||
| $96.38M+8.5% | $88.84M-9.2% | $97.79M-22.0% | $125.33M+5.7% | ||
| $3K+50.0% | $2K0.0% | $2K+100% | $1K— | ||
| $958.43M+41.4% | $677.86M+15.3% | $587.94M+46.1% | $402.39M+21.6% | ||
| -$711.3M-18.1% | -$602.31M-17.4% | -$513.01M-27.8% | -$401.44M-70.4% | ||
| -$192K+95.2% | -$4.03M— | —— | —— | ||
| $246.94M+245% | $71.53M-4.6% | $74.94M+7,796% | $949K-99.0% | ||
| $343.32M+114% | $160.36M-7.2% | $172.73M+36.8% | $126.28M-41.0% | ||
| $183K-15.7% | $217K-28.6% | $304K-76.9% | $1.32M+18.9% | ||
| $9.44M+12.6% | $8.38M-12.5% | $9.58M-12.4% | $10.94M— | ||
| $9.44M+12.6% | $8.38M-12.5% | $9.58M-12.4% | $10.94M— | ||
| $183K-15.7% | $217K-28.6% | $304K-76.9% | $1.32M+18.9% | ||
| $9.44M+12.6% | $8.38M-12.5% | $9.58M-12.4% | $10.94M— | ||
| $183K-15.7% | $217K-28.6% | $304K-76.9% | $1.32M+18.9% | ||
| $20.28M+57.7% | $12.86M+4.7% | $12.28M-32.8% | $18.29M-39.0% | ||
| $70.14M+10.4% | $63.56M+2.7% | $61.89M+1.4% | $61.06M+64.2% | ||
| $3K+50.0% | $2K0.0% | $2K+100% | $1K— | ||
| $379K-3.1% | $391K+10.5% | $354K+10.6% | $320K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Taysha Gene Therapies, Inc. cover its short-term obligations?
- Its current ratio is 14.04 — current assets exceed current liabilities.
- Where does Taysha Gene Therapies, Inc.'s balance sheet data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.